Porcine Vaccines Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 2.05 Billion |
| Market Size (2029) | USD 2.95 Billion |
| CAGR (2024 - 2029) | 7.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Porcine Vaccines Market Analysis
The Global Porcine Vaccine Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.95 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).
The sudden outbreak of COVID-19 majorly impacted all the markets. With the focus primarily shifted to combat COVID-19, all other research and development are on hold. In July 2020, the Center for Disease Control and Prevention (CDC) provided specific guidelines to veterinary professionals for treating animals during COVID-19. Many government agencies have also recommended prioritizing urgent and emergency visits to clinics and hospitals. Furthermore, most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the global shortage of healthcare facilities and COVID-19 testing laboratories, according to the OIE (World Organization for Animal Health). However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. Prestige Animal Hospitals, for example, has taken precautionary measures when treating animals. It also launched the 'Drop Off Exams' program, which allows owners to drop off their pets for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. As a result, the companion animal vaccine market is experiencing a slight short-term negative impact, owing to lower veterinary visits during COVID-19. Thus, COVID-19 is expected to impact the porcine vaccine market slightly.
Additionally, the growing R&D activities by the key players for discovering novel porcine vaccines to treat diseases and rising product approvals are expected to aid in the positive growth of the studied market over the forecast period. For instance, in May 2021, the Classical Swine Fever (CSF) vaccine was launched under the Raksha Class by Indian Immunologicals Limited (IIL) brand name. Thus, rising product launches anticipated market growth over the forecast period.
According to the Congress Budget Office report in April 2021, the pharmaceutical industry spent USD 83 billion on research and development. These costs were paid for various activities, including discovering and testing new drugs, developing incremental innovations like product extensions, and conducting clinical trials for safety monitoring or marketing purposes. Thus rising in R&D spending boosts the market over the forecast period.
PRRS (Porcine Reproductive and Respiratory Syndrome) is still a common disease in pig farms, causing financial losses due to its adverse effects on reproduction, growth, and clinical illness. As a result, market innovation to meet customer demand has been ongoing. For example, in April 2021, Ahmedabad-based company Hester Bioscience got the right to commercially produce classical swine fever and sheep pox vaccines in India. Scientists develop these two vaccines from the Indian Veterinary Research Institute (IVRI), Izatnagar, under the Indian Council of Agricultural Research (ICAR). Also, in April 2021, the Argentine laboratory Vetanco partnered with Pharmgate Animal Health to distribute the Circo/MycoGard vaccine in Argentina and Latin America. The vaccine protects pigs against both PCV-2 and Mycoplasma hyopneumoniae.
Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, high expenses of maintaining and handling storage conditions and chance of reverse reaction from vaccines significantly hinder the market's growth.
Porcine Vaccines Market Trends
This section covers the major market trends shaping the Porcine Vaccine Market according to our research experts:
Porcine Circovirus Associated Disease is Expected to Witness a Healthy Growth
PCV (Porcine Circovirus) is the smallest non-enveloped, single-stranded DNA virus, which replicates autonomously in eukaryotic cells, using the host polymerase for genome amplification. PCV can be spread through direct contact with an infected pig. PCV2 is the single-stranded DNA (ssDNA) virus with the highest mutation and recombination rate of all single-stranded DNA (ssDNA) viruses. PCV is one of the most important infectious agents affecting pig productivity worldwide.
Furthermore, according to Henna's article published in MDPI Viruses in January 2021, the global prevalence and status of PCV have resulted in a seropositivity rate of 20-80% in pigs, as well as a very high incidence rate of 60%, with a culling rate of 40% in severely affected pig farms.
Commercially available PCVAD vaccines can be of many types, mainly based upon the dosage, packaging size, age of the pig it is used on, and virus type. Some of the major brands manufacturing and selling porcine vaccines for PCVAD, globally, are Boehringer Ingelheim, Merck, and Zoetis, among others. The first FLEX Family swine vaccine for PCV2 protection in a single injection was Ingelvac CircoFLEX, by Boehringer Ingelheim. Hence, it is one of the revolutionary PCV2 vaccines on the market.
Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.
North America Holds a Significant Market Share
Increasing pork consumption, the growing prevalence of various swine diseases, and rising per capita animal healthcare expenditure are the factors the United States is expected to retain its large market share.
In the United States, advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. Moreover, technological advances in the vaccine field and well-established healthcare infrastructure are also considerably fueling the regional market's growth. For instance, in March 2022, Boehringer Ingelheim launched the porcine parvovirus vaccine ReproCyc ParvoFLEX which provides safe, efficacious protection for healthy sows and gilts six months of age or older against reproductive failure caused by porcine parvovirus.
Furthermore, according to the Agricultural Economic Insights (AEI) report, meat consumption in the United States increased in 2020 when studied from 1970 to 2020. Although poultry, beef, and pork consumption pattern broadly vary, it increases the risk of swine diseases.
Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.
Porcine Vaccines Industry Overview
The porcine vaccines market is fairly competitive and consists of several major players including Hipra, Zoetis, Elanco Inc, Boehringer Ingelheim, and Vetoquinol. Most of these major players enjoy a global presence and are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion as well as farm animals.
Porcine Vaccines Market Leaders
-
Zoetis Inc.
-
Hipra
-
Elanco
-
Boehringer Ingelheim
-
Vetoquinol
*Disclaimer: Major Players sorted in no particular order
Porcine Vaccines Market News
- In June 2022, Merck Animal Health received license approval in the United States from the Department of Agriculture (USDA) for its Circumvent CML vaccine. Merck issued a press release that claims Circumvent CML is the first-ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d.
- In April 2022, Scientists with the United States Department of Agriculture's Agricultural Research Service (ARS) announced that a vaccine candidate for African Swine Fever (ASF) passed an important safety test required for regulatory approval, moving the vaccine one step closer to commercial availability.
Porcine Vaccines Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growth in Demand for Pork and Gelatin
- 4.2.2 Rise in Prevalence of Swine Diseases
- 4.2.3 Increase in R&D Expenditure for Innovation of Vaccines
-
4.3 Market Restraints
- 4.3.1 High Expenses of Maintaining and Handling Storage Conditions
- 4.3.2 Chance of Reverse Reaction from Vaccines
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Target Disease
- 5.1.1 Diarrhea
- 5.1.2 Swine Influenza
- 5.1.3 Arthritis
- 5.1.4 Bordetella Rhinitis
- 5.1.5 Porcine Reproductive and Respiratory Syndrome (PRRS)
- 5.1.6 Porcine Circovirus Associated Disease (PCVAD)
- 5.1.7 Other Target Diseases
-
5.2 By Technology
- 5.2.1 Inactivated Vaccines
- 5.2.2 Live Attenuated Vaccines
- 5.2.3 Toxoid Vaccines
- 5.2.4 Recombinant Vaccines
- 5.2.5 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 COMPANY PROFILES
- 6.1.1 IDT Biologika GmbH
- 6.1.2 HIPRA
- 6.1.3 Ceva Sante Animale
- 6.1.4 Elanco
- 6.1.5 Arko Laboratories Ltd
- 6.1.6 Intervet Inc.
- 6.1.7 Merial
- 6.1.8 Vetoquinol
- 6.1.9 Zoetis Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPorcine Vaccines Industry Segmentation
Porcine Vaccines are a clinical and administrative drug that ameliorates swine health by protecting them from various bacteria, viruses, and other pathogens. The market is segmented by Target Disease (Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCVAD), Other Target Diseases), Technology (Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Target Disease | Diarrhea | |
| Swine Influenza | ||
| Arthritis | ||
| Bordetella Rhinitis | ||
| Porcine Reproductive and Respiratory Syndrome (PRRS) | ||
| Porcine Circovirus Associated Disease (PCVAD) | ||
| Other Target Diseases | ||
| By Technology | Inactivated Vaccines | |
| Live Attenuated Vaccines | ||
| Toxoid Vaccines | ||
| Recombinant Vaccines | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Porcine Vaccines Market Research FAQs
How big is the Global Porcine Vaccine Market?
The Global Porcine Vaccine Market size is expected to reach USD 2.05 billion in 2024 and grow at a CAGR of 7.5% to reach USD 2.95 billion by 2029.
What is the current Global Porcine Vaccine Market size?
In 2024, the Global Porcine Vaccine Market size is expected to reach USD 2.05 billion.
Who are the key players in Global Porcine Vaccine Market?
Zoetis Inc., Hipra, Elanco, Boehringer Ingelheim and Vetoquinol are the major companies operating in the Global Porcine Vaccine Market.
Which is the fastest growing region in Global Porcine Vaccine Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Porcine Vaccine Market?
In 2024, the North America accounts for the largest market share in Global Porcine Vaccine Market.
What years does this Global Porcine Vaccine Market cover, and what was the market size in 2023?
In 2023, the Global Porcine Vaccine Market size was estimated at USD 1.91 billion. The report covers the Global Porcine Vaccine Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Porcine Vaccine Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Porcine Vaccines Industry Report
The Porcine Vaccines Market is segmented by target disease, technology, and geography. It covers various diseases such as diarrhea, swine influenza, arthritis, bordetella rhinitis, porcine reproductive and respiratory syndrome (PRRS), porcine circovirus associated disease (PCVAD), and other target diseases. The market analysis includes inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, and others. The report provides a comprehensive industry analysis, offering insights into market trends, market growth, and the market forecast.
The industry reports indicate a robust market outlook with significant industry growth rate. The market segmentation by geography includes North America, Europe, Asia-Pacific, Middle East & Africa, and South America. The market research highlights the market leaders and their market share, along with an in-depth market overview and market review.
The industry information includes a detailed industry size and industry statistics, with a focus on market data and market value. The report example provided is available as a free report PDF download. The industry research emphasizes the market predictions and market segmentation, providing a thorough market analysis.
The market forecast shows a positive market growth, driven by the increasing demand for porcine vaccines across various regions. The market trends are highlighted in the industry outlook, showcasing the potential for future market expansion. The report pdf and research companies involved in the market provide valuable insights into the industry sales and industry trends.
In summary, the porcine vaccines market is poised for significant growth, with a detailed market segmentation and a comprehensive industry overview. The industry statistics and market data offer a clear picture of the market value, supported by the market predictions and market outlook. The report provides a thorough market review and industry research, making it an essential resource for understanding the porcine vaccines market.
